Skip to content
Screener

Ultragenyx Pharmaceutical RARE Q1 2026 earnings

Reported May 5, 2026 · After market close

Revenue$136.0MMiss by $22.2M
EPS-$1.84Miss by $0.35
Revenue estimate$158.2M
EPS estimate-$1.49

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$182.9M
EPS estimate-$0.65

Financials

Q1 2026

Income statement

See full
Revenue$136.0M-2.2%
Operating income-$169.0M-18.2%
Net income-$185.0M-22.5%
EPS (diluted)-$1.84-17.2%

Balance sheet

See full
Cash & equivalents$175.0M+37.8%
Total equity-$236.0M-264%
Total assets$1.3B-1.2%

Cash flow

See full
Operating cash flow-$197.0M-18.7%
CapEx$1.0M0.0%
Free cash flow-$198.0M-18.6%

Valuation & ratios

Valuation

as of 03/31/26
See full
Market cap$2.06B-39.4%
P/S3.1×-2.7×

Profitability

See full
Operating margin-83.7%-3.1pp
Net margin-90.9%-2.1pp
FCF margin-75.1%+10.6pp

Returns & leverage

See full
Current ratio2×-0.4×

Segments

By geography

See full
North America$59.0M+1.7%
Latin America$42.0M-23.6%
EMEA$31.0M+34.8%
Asia Pacific$4.0M+33.3%

By product

See full
Collaboration And Royalty$93.0M-9.7%
Royalty$47.0M-2.1%
Non Cash Royalty$20.0M+5.3%

FAQ

When did Ultragenyx Pharmaceutical report Q1 2026 earnings?
Ultragenyx Pharmaceutical (RARE) reported Q1 2026 earnings on May 5, 2026 after market close.
What were Ultragenyx Pharmaceutical's Q1 2026 revenue and EPS?
Ultragenyx Pharmaceutical reported revenue of $136.0M and eps of $-1.84 for Q1 2026.
Did Ultragenyx Pharmaceutical beat estimates in Q1 2026?
Revenue missed the consensus estimate of $158.2M by $22.2M. EPS missed the consensus estimate of $-1.49 by $0.35.
How did Ultragenyx Pharmaceutical's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue declined 2.4% from $139.3M a year earlier and eps declined 17.2% from $-1.57.
Where can I find Ultragenyx Pharmaceutical's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-206368) and the 10-Q periodic report (0001193125-26-206960) directly on SEC EDGAR. The filing index links above go to sec.gov.